Shattuck Labs, Inc.

STTK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-48.8M $-75.4M $-87.3M $-101.9M $-45.0M $-36.6M $-24.0M
Depreciation & Amortization $3.7M $3.8M $4.0M $3.1M $1.4M $600.0K $500.0K
Depreciation $3.7M $3.8M $4.0M $3.1M $1.4M $618.0K $537.0K
Amortization — — — — — — —
Stock-Based Compensation $7.0M $9.5M $6.9M $6.5M $5.5M $1.3M $461.0K
Net Cash from Operating Activities $-39.9M $-60.5M $-81.2M $-94.5M $-57.1M $-33.7M $-21.0M
Investing Activities
Capital Expenditures $71.0K $59.0K $407.0K $11.6M $7.9M $727.0K $470.0K
Business Acquisitions — — — — — — —
Net Cash from Investing Activities $-7.9M $-8.5M $110.9M $49.4M $-10.4M $-146.3M $-3.6M
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $44.6M $787.0K $48.6M $171.0K $1.9M $330.9M $-64.0K
Net Change in Cash $-3.2M $-68.2M $78.2M $-44.9M $-65.6M $150.9M $-24.6M
Free Cash Flow $-40.0M $-60.6M $-81.6M $-106.1M $-65.0M $-34.4M $-21.4M